DEFINITIVE CONTRACT
Active75F40126C00068
Department of Health and Human Services › Food and Drug Administration › FDA OFFICE OF ACQ GRANT SVCS
$933K
obligated · signed 1 week ago
FIRM FIXED PRICE AWARD BAA FY2600123: A MULTIOMICS APPROACH TO IMPROVING THE IDENTIFICATION OF THE SIDE EFFECTS OF IMMUNE CHECKPOINT INHIBITORS (ICIS) CONTRACTING OFFICER (CO) NAME: IAN WEISS E-MAIL: IAN.WESISS@FDA.HHS.GOV CONTRACT SPECIALI
Performance timeline
Start
Sep 30, 2026
Current end
Sep 29, 2027
Potential end
Sep 29, 2029
with all options
Loading status
Estimated start: Sep 29, 2028
DANA-FARBER CANCER INSTITUTE, INC.
Contract 75F40126C00068
UEI
DPMGH9MG1X67
Parent Company
DANA-FARBER CANCER INSTITUTE, INC.
Capabilities & Certifications
Headquarters Location
Congressional District: 07
Current Obligation
$933,028
Base + Exercised Options
$933,028
Total Ceiling Value
$1,583,356
Contract Type
FIRM FIXED PRICE
Multi-Year Contract
NO
NAICS
SPECIALTY (EXCEPT PSYCHIATRIC AND SUBSTANCE ABUSE) HOSPITALS
PSC
GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; BASIC RESEARCH
Place of Performance
Congressional District: 08
Awarding Agency
Top-tier agency
Food and Drug Administration
Sub-tier agency
FDA OFFICE OF ACQ GRANT SVCS
Office
Funding Agency
Top-tier agency
Food and Drug Administration
Sub-tier agency
FDA OFFICE OF ACQ GRANT SVCS
Office
Solicitation procedures, competition exceptions, labor standards and account totals.